本文源自：财华网 【财华社讯】派格生物医药-B(02565.HK)公布，公司近日接获基石投资者的通知，基石投资者益泽康瑞 医药(香港)有限公司同意自原禁售期(经第一次禁售延长予以延长)届满日期起至2026年4月30日不会以任 何方式减持任何相关H股("第二次禁售延长")。截至本公告日期，基石投资者合共持有958.45万股H股， 占公司已发行H股总数约3.43%。 公司认为，第二次禁售延长表明基石投资者基于公司对推进技术方面的研发能力及在重大临床里程碑方 面取得的重大进展，对公司的未来前景充满信心。基石投资者亦将持续审阅公司业绩，且或会基于实时 发展及所实现的里程碑，考虑进一步延长禁售期。 ...

Core Viewpoint - The stock of Pagoda Biopharmaceuticals-B (02565.HK) opened over 7% higher on November 27, closing at HKD 70.00 per share, an increase of 7.03% due to the announcement of an extended lock-up period by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [2] Group 1: Lock-up Period Extension - Yizhe Kangrui has agreed not to reduce its holdings of H-shares from the original lock-up expiration date until December 31, 2025, extending the lock-up period by 35 days [3] - The extension reflects Yizhe Kangrui's confidence in Pagoda Biopharmaceuticals' technological advancements and significant progress in major clinical milestones [2][3] - Yizhe Kangrui currently holds 9.5845 million H-shares, representing approximately 3.43% of the total issued H-shares of the company [3] Group 2: Company Background and Recent Developments - Pagoda Biopharmaceuticals, established in 2008, focuses on the research and development of innovative therapies for chronic diseases, particularly in the field of metabolic disorders [5] - The company recently received approval for its first product, PB-119 (Vepidna Injection), aimed at improving blood sugar control in adults with type 2 diabetes [6] - Since its listing, Pagoda Biopharmaceuticals has seen a stock price increase of 438.46% over 129 trading days from May 27 to the present [6] Group 3: Financial Performance and Market Outlook - Pagoda Biopharmaceuticals has reported losses of CNY 279 million, CNY 283 million, and CNY 93.62 million for the years 2023, 2024, and the first half of 2025, respectively [6] - A recent report from Softbank China has given Pagoda Biopharmaceuticals a strong buy rating with a target price of HKD 101.80, citing the clinical advantages of PB-119 and potential revenue growth from 2026 to 2029 [6]

Core Viewpoint - The company has received notification from its cornerstone investor, Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., agreeing to extend the lock-up period for its H shares until December 31, 2025, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor will not reduce its holdings in any related H shares from the expiration of the original lock-up period [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Core Viewpoint - The announcement highlights the extension of the lock-up period for cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1: Lock-up Agreement - The company entered into a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical, which includes a lock-up commitment for a total of 9,584,500 H shares for a period of 6 months from the listing date [1] - The cornerstone investor currently holds 9,584,500 H shares, representing approximately 3.43% of the company's total issued H shares [1] Group 2: Extension of Lock-up Period - The cornerstone investor has agreed not to reduce their holdings of the relevant H shares from the end of the original lock-up period until December 31, 2025 [1] - The company interprets the extension of the lock-up period as a sign of the cornerstone investor's confidence in the company's ability to advance its technological research and achieve significant clinical milestones [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]